Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05783817 · ClinicalTrials.gov registry record · Phase 2

MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)

A Phase 2 study of Obsessive - Compulsive Disorder, sponsored by Carolyn Rodriguez.

Recruiting
Registry status
Phase 2
Development phase
40
Enrollment target
1
Study location

NCT05783817 is a Phase 2 study of Obsessive - Compulsive Disorder that is actively recruiting participants, run by Carolyn Rodriguez. The registered enrollment target is 40 participants, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05783817, a Phase 2 study of Obsessive - Compulsive Disorder, is actively recruiting participants, sponsored by Carolyn Rodriguez.

RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The study assesses the safety and preliminary effectiveness of MDMA-assisted cognitive behavioral therapy in participants diagnosed with obsessive-compulsive disorder (OCD).

Interventions

  • BEHAVIORAL Cognitive Behavioral Therapy (CBT)
  • DRUG Methamphetamine
  • DRUG 3,4-Methyl enedioxy methamphetamine

Study Locations (1)

California

  • Stanford University Medical Center - Palo Alto

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-09-10
Est. Completion 2026-12-01
Phase Phase 2

Sponsor

Carolyn Rodriguez

2 total trials

What the Registry Record Tells You About NCT05783817

The ClinicalTrials.gov registry entry for NCT05783817 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (98% lower). The listed sponsor is Carolyn Rodriguez, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Obsessive - Compulsive Disorder appearing as the primary indexed condition, and to 3 interventions - of which Cognitive Behavioral Therapy (CBT) is the first listed.

NCT05783817 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05783817 about?

NCT05783817 is a clinical study titled "MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)". The study assesses the safety and preliminary effectiveness of MDMA-assisted cognitive behavioral therapy in participants diagnosed with obsessive-compulsive disorder (OCD).

What is the current status of trial NCT05783817?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-09-10. Estimated completion is 2026-12-01.

What conditions does trial NCT05783817 study?

This clinical trial studies the following conditions: Obsessive - Compulsive Disorder.

What interventions are being tested in trial NCT05783817?

The interventions under investigation include: Cognitive Behavioral Therapy (CBT) (BEHAVIORAL), Methamphetamine (DRUG), 3,4-Methyl enedioxy methamphetamine (DRUG).

Who is sponsoring clinical trial NCT05783817?

This trial is sponsored by Carolyn Rodriguez, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05783817 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obsessive - Compulsive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.